Overall Status

Recruiting (69)

Active, not recruiting (34)

Not yet recruiting (28)

Completed (12)

Terminated (8)

Suspended (2)

Unknown status (1)

Withdrawn (1)

Phase

phase 2 (82)

phase 1 (24)

phase 1/phase 2 (13)

phase 3 (12)

early phase 1 (6)

phase 2/phase 3 (5)

phase 4 (4)

n/a (1)

Study Documents

Intervention Type

drug (152)

biological (30)

procedure (21)

other (15)

radiation (13)

device (2)

combination product (1)

dietary supplement (1)

Funder Type

Other (92)

Industry (31)

NIH (31)

U.S. Fed (1)

Study Type

Interventional (147)

Observational (7)

Observational [Patient Registry] (1)

Lynparza

Showing 151 - 155 of 155

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Breast Cancer Trial in Worldwide (Olaparib, Placebo)

Active, not recruiting

Has Results

Breast Cancer

Olaparib
Placebo

Anchorage, Alabama
+698 more

Nov 25, 2022

Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8 Trial in United States (Olaparib, Pembrolizumab)

Recruiting

Metastatic Pancreatic Adenocarcinoma
Stage IV Pancreatic Cancer AJCC v8

Olaparib
Pembrolizumab

Anchorage, Alaska
+513 more

Jan 28, 2023

Endometrial Undifferentiated Carcinoma, Endometrioid Adenocarcinoma, Recurrent Endometrial Serous Adenocarcinoma Trial in United

Recruiting

Endometrial Undifferentiated Carcinoma
+6 more

Capivasertib
+4 more

Birmingham, Alabama
+741 more

Feb 2, 2023

Advanced Cancer, Ovarian Cancer, Endometrial Cancer Trial in Spain (PM01183 + olaparib)

Unknown status

Advanced Cancer
+3 more

PM01183 + olaparib

Córdoba, Andalucía, Spain
+5 more

Jun 21, 2017

Breast Cancer Trial in Cambridge (Olaparib, Paclitaxel and Carboplatin)

Recruiting

Breast Cancer

Olaparib
Paclitaxel and Carboplatin

Cambridge, Cambridgeshire, United Kingdom

Cambridge University Hospitals NHS Foundation Trust & the Univer

May 10, 2017